Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer

[1]  D. Quinton,et al.  Unit Costs of Health and Social Care 2004 , 2004 .

[2]  R. James,et al.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial , 2000, The Lancet.

[3]  T. Hickish,et al.  Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU. , 1999, European journal of cancer.

[4]  Christian Jacques,et al.  Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer , 1998, The Lancet.

[5]  R. Labianca,et al.  Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer , 1998, The Lancet.

[6]  A. Padhani,et al.  A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  F. Lévi,et al.  Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer , 1997, The Lancet.

[8]  P. Rougier,et al.  Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Culine,et al.  Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Cassidy,et al.  Attitudes and practice in the management of metastatic colorectal cancer in Britain. Colorectal Cancer Working Party of the UK Medical Research Council. , 1997, Clinical oncology (Royal College of Radiologists (Great Britain)).

[11]  T. Chou,et al.  Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Jones Sf,et al.  Topoisomerase I inhibitors: topotecan and irinotecan. , 1996, Cancer practice.

[13]  H. Burris,et al.  Topoisomerase I inhibitors: topotecan and irinotecan. , 1996, Cancer practice.

[14]  B. van Triest,et al.  Current chemotherapeutic possibilities in the treatment of colorectal cancer. , 1995, European journal of cancer.

[15]  D. V. Von Hoff,et al.  Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units. , 1994, Anti-cancer drugs.

[16]  J. Dierlamm,et al.  Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. A multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO). , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  Colorectal carcinoma: current problems and future perspectives. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  J. Verweij,et al.  Topoisomerase I inhibitors: topotecan and irenotecan. , 1994, Cancer treatment reviews.

[19]  S. Iacobelli,et al.  Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. , 1993, European journal of cancer.

[20]  P. Piedbois.  Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. Wilson.  The British National Formulary. , 1963, The Practitioner.